TRAUMATIC BRAIN INJURY. RETHINKING PHARMACOLOGICAL CLINICAL TRIALS in an ORPHAN PATHOLOGY [0.03%]
颅脑损伤的药物治疗临床试验困境与出路：一种罕见疾病的视角
Roberto Imberti
Roberto Imberti
Introduction: Every year more than 50 million people in the world experience a traumatic brain injury (TBI). In its more severe form the mortality is high, and survivors can be very disabled. Nevertheless, there are curre...
Confounding adjustment with propensity scores for overlap weighting in observational studies: a concise primer [0.03%]
倾向得分在观察研究中进行重叠加权对照调整：简明教程
John G Rizk
John G Rizk
Introduction: Overlap weighting has emerged as a valuable method for addressing confounding in observational studies, particularly in real-world data settings characterized by imbalanced covariates and limited overlap bet...
Current state, challenges, unmet needs, and future directions in the pharmacological treatment of biliary tract cancer [0.03%]
胆道癌药物治疗的现况、挑战、未满足需求和未来方向
Michael H Storandt,Amit Mahipal
Michael H Storandt
Introduction: There has been a significant change in the treatment paradigm of biliary tract cancers (BTCs) in recent years with the introduction of chemoimmunotherapy and the development of targeted agents. In the presen...
Current status of biological therapy use for older adults with severe asthma [0.03%]
生物制剂治疗重度哮喘老年人的现状
Alessandra Tomasello,Alida Benfante,Lorena Gentile et al.
Alessandra Tomasello et al.
Introduction: The management of severe asthma in older adults is an increasingly important clinical challenge. Aging-associated structural, functional, and immunological changes contribute to a distinct geriatric asthma p...
Unravelling the genetic complexity of drug-resistant epilepsy: a critical narrative review [0.03%]
解开药物抵抗性癫痫的遗传复杂性的故事性叙述批判性综述
Martina Giacon,Salvatore Terrazzino
Martina Giacon
Introduction: Drug-resistant epilepsy (DRE) affects 30% of epilepsy patients and represents a major therapeutic challenge. Understanding its genetic determinants is crucial for the development of effective precision medic...
Prescribing pattern of disease-modifying antirheumatic drugs in Scotland (2019-2023): a population-based retrospective cohort study [0.03%]
苏格兰（2019-2023年）疾病修饰抗风湿药的处方模式：基于人群的回顾性队列研究
Amanj Kurdi,Euan Proud,Laura Stobo et al.
Amanj Kurdi et al.
Background: The increasing complexity of biologic and targeted therapies for inflammatory rheumatic diseases necessitates robust, real-world evidence to guide clinical decision-making. Scotland's newly established Homecar...
Current and emerging pharmacological treatment options for patients with dry eye disease [0.03%]
当前和新兴的药物治疗选项在干眼病患者中的应用
Feyza Cukurova,Giulia Coco,Filippo Lixi et al.
Feyza Cukurova et al.
Introduction: To provide an up-to-date overview of current pharmacological treatments and promising emerging therapies for dry eye disease (DED), a multifactorial and increasingly prevalent ocular surface disorder. ...
Mehmet Sofuoglu,Joao P De Aquino,R Ross MacLean
Mehmet Sofuoglu
Clinical pharmacologic considerations for antibody drug conjugates in gynecologic cancers [0.03%]
妇科肿瘤抗体药物偶联物的临床药理学考量
Victoria M Ettorre,Luca Palmieri,Alessandro D Santin
Victoria M Ettorre
Introduction: The mainstay of treatment for gynecologic cancers includes surgical debulking followed in a subset of patients by chemotherapy, radiation, hormonal therapy and immunotherapy. In the last 10 years, antibody -...
Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy [0.03%]
斯帕森坦：一种内皮素受体和血管紧张素II受体拮抗剂，用于治疗IgA肾病
Gates B Colbert,Hector M Madariaga,Anna Gaddy et al.
Gates B Colbert et al.
Introduction: IgA Nephropathy (IgAN) is the most common primary glomerulonephritis. For decades, the only medication treatments that were widely accepted were the use of renin-angiotensin aldosterone inhibitors and cortic...